Oral ibandronic acid inferior to IV zoledronic acid for metastatic breast cancer to bone

Study Type:Therapy

OE Level Evidence:2

Journal Level of Evidence:N/A

Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial

Lancet Oncol. 2014 Jan;15(1):114-22. doi: 10.1016/S1470-2045(13)70539-4.

Contributing Authors: P Barrett-Lee A Casbard J Abraham K Hood R Coleman P Simmonds H Timmins D Wheatley R Grieve G Griffiths N Murray

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Explore some of our unlocked reports below!

Treatment of osteoarthritis: A role for education programmes?

The prevalence of intimate partner violence in women presenting to orthopaedic clinics

Osteoporosis Choice decision aid improves treatment experience of clinicians and patients

Protein-Rich nutritional supplementation shows limited efficacy in elderly hip fractures

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.

Oral ibandronic acid inferior to IV zoledronic acid for metastatic breast cancer to bone

To view the full report, start your 30-day free trial today

Explore some of our unlocked reports below!

Continuing Medical Education Credits

Please be patient while we setup your OrthoEvidence account.

Please be patient
while we setup your
OrthoEvidence account.